Bayer AG has cemented the scientific case for its most promising pipeline asset, asundexian, with the full publication of pivotal Phase III trial data in the New England Journal of Medicine. The results validate a novel approach to stroke prevention and mark a critical milestone for the German conglomerate, which has seen its shares surge over 93% in the past year on hopes of an operational turnaround.
The OCEANIC-STROKE study, involving more than 12,300 high-risk patients globally, demonstrated that the oral inhibitor reduced the risk of ischemic stroke by 26% compared to a placebo. Crucially, the risk of major bleeding did not increase. The drug’s performance was particularly notable in preventing severe outcomes, cutting the rate of disabling or fatal strokes by 31%. In the treatment group, these severe events occurred in just 2.1% of patients.
This success is a significant reversal for a drug class that has seen numerous failures. Asundexian works by selectively blocking Factor XIa, a protein key to clot formation, while largely sparing the body’s natural wound-healing mechanisms. The positive data come nearly three years after an earlier study for a different indication was halted, making the current outcome a substantial win for Bayer’s research division.
Should investors sell immediately? Or is it worth buying Bayer?
Financially, the company is entering this crucial phase with improved flexibility. Net financial debt recently fell by just over 8% to approximately €30 billion. Management has reaffirmed its full-year outlook, targeting sales of up to €47 billion and core operating earnings of around €10 billion. According to U.S. pharma chief Sebastian Guth, potential new U.S. tariffs are already fully factored into planning for 2026.
On the governance front, Bayer is preparing for its virtual Annual Stockholders’ Meeting on April 24. Shareholders are set to receive an unchanged dividend of €0.11 per share. The meeting will also see a refresh of the supervisory board, with long-standing members Paul Achleitner and Colleen Goggins stepping down. The company has proposed Marcel Smits and Alfred Stern as their successors to help steer the ongoing strategic overhaul.
The stock recently traded around €40.69, holding substantial gains for the year and maintaining a comfortable buffer of nearly 20% above its 200-day moving average. With the clinical data now formally published, the path is clear for Bayer to submit asundexian for global regulatory approvals, though a specific launch timeline has not yet been disclosed. The company’s next operational test arrives in May with the release of first-quarter figures, which must demonstrate that the confirmed annual guidance is backed by solid day-to-day business performance.
Ad
Bayer Stock: Buy or Sell?! New Bayer Analysis from April 21 delivers the answer:
The latest Bayer figures speak for themselves: Urgent action needed for Bayer investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from April 21.
Bayer: Buy or sell? Read more here...
